FDA Approves First-In-Class HIV Treatment Option
by Press Release from Outbreak News Today on (#675PP)
Gilead Sciences, Inc. announced this week that Sunlenca(R) (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. Sunlenca has a multi-stage mechanism of action distinguishable from other currently approved classes [...]
The post FDA Approves First-In-Class HIV Treatment Option appeared first on Outbreak News Today.